Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03754985
Other study ID # 0024-16-ASF
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 2016
Est. completion date October 2018

Study information

Verified date November 2018
Source Assaf-Harofeh Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prospective analysis included patients, 18 years or older, scheduled for 60 daily HBOT sessions between 2016-2018. Each session was 90 min of 100% oxygen at 2 ATA with 5 minutes air breaks every 20 min, five days per week. Pulmonary functions,measured at baseline and after HBOT,included forced vital capacity (FVC), forced expiratory volume in one second (FEV1), peak expiratory flow rate (PEF).


Description:

After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session.

Pulmonary function Measurements of pulmonary functions were performed using the MiniSpir testing apparatus (MIR- Medical International Research, USA). The equipment was calibrated using a 3-liter syringe before performing measurements according to the manufacturer's instructions. Measurements were performed by a trained technician. The forced expiratory maneuvers were performed as recommended by the guidelines[13].

The forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and peak expiratory flow rate (PEF) were taken as the highest readings obtained from at least three satisfactory forced expiratory maneuvers. Mean forced mid-expiratory flow rate (FEF25-75%) and forced expiratory flow rates at 25, 50 and 75% of FVC expired (FEF25%, FEF50% and FEF75%) were taken as the best values from flow-volume loops not differing by >5% from the highest FVC.


Recruitment information / eligibility

Status Completed
Enrollment 105
Est. completion date October 2018
Est. primary completion date September 2018
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- 18 and older patients

- scheduled for 60 HBOT sessions for any indication

Exclusion Criteria:

- Active smokers were excluded but patients who quit smoking more than six months prior to inclusion were allowed in the study.

- active smoking

- severe known pulmonary disease

- chest pathology incompatible with HBOT

- inner ear disease

- claustrophobia

- other neurological conditions

- pregnancy

- previous HBOT within six months prior to inclusion

- the inability to sign informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Hyperbaric oxygen therapy
The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication. After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session. After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session.

Locations

Country Name City State
Israel Amir Hadanny Zerifin

Sponsors (1)

Lead Sponsor Collaborator
Assaf-Harofeh Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary forced vital capacity (FVC) change within 3 months
Primary forced expiratory volume in one second (FEV1) change within 3 months
Primary peak expiratory flow rate (PEF) change within 3 months
Primary forced mid-expiratory flow rate (FEF25-75%) change within 3 months
Primary FEV1/FVC ratio change within 3 months
See also
  Status Clinical Trial Phase
Completed NCT04291911 - Retrospective Multicentre Observational Study on the Incidence of Hyperoxia in Non-intubated Patients in Intensive Care in Belgium Study OxSIZgen
Completed NCT02917668 - Evaluation of the Risk of Hyperoxia-induced Hypercapnia in Obese Cardiac Surgery Patients N/A
Not yet recruiting NCT02201875 - Intrinsic Periodic Pattern of Breathing N/A
Completed NCT05770583 - The Effectiveness of FiO2 Titration Guided by the Oxygen Reserve Index in Preventing Hyperoxia. N/A
Not yet recruiting NCT02553668 - Proteomics for Identification of Hyperoxia-induced Changes in Protein Expression N/A
Completed NCT01978158 - Effects of Oxygen Status on Endotoxemia Induced Inflammation and Hypoxia Inducible Factor-1α Phase 1/Phase 2
Completed NCT03268590 - Neuroimaging During Pure Oxygen Breathing Phase 4
Active, not recruiting NCT04133740 - Oxygenation Targets in Cardiac Surgery Patients - a Before-and-after Study Phase 4
Recruiting NCT04866342 - Servo Controlled Oxygen Targeting (SCO2T) Study: Masimo vs. Nellcor N/A
Completed NCT05150418 - Supplemental Oxygen in Hypovolemia Phase 1
Terminated NCT03550469 - Computer-assisted Oxygen Therapy Weaning in Critically Ill Children N/A
Recruiting NCT04413097 - Delayed Cord Clamping With Oxygen In Extremely Low Gestation Infants N/A
Completed NCT03464695 - Automated Oxygen Delivery by O2matic to Patients Admitted With an Exacerbation in COPD N/A
Recruiting NCT04269161 - NICU Oxygen Control Study N/A
Completed NCT02384616 - Hyperoxygenation in Anesthetized Children N/A
Unknown status NCT01348906 - Intermittent Normoxia Reduces Myocardial Reperfusion Injury N/A
Completed NCT04420897 - The Effect of Intraoperative Arterial Oxygen Pressures on Early Post-Operative Patient and Graft Survival in Living Donor Kidney Transplantation
Completed NCT03930979 - The Effect of Hyperoxia on Cardiac Output
Not yet recruiting NCT06326372 - The Effect of Intraoperative Hyperoxemia on Postoperative Delirium in Geriatric Patients
Recruiting NCT05412810 - Oxidative Lipidomic Biomarkers During Mechanical Ventilation in Critically Ill Patients (OXY-BAL).